InflaRx NV (IFRX)
1.44
-0.04
(-2.70%)
USD |
NASDAQ |
Oct 15, 16:00
1.45
+0.01
(+0.69%)
After-Hours: 20:00
InflaRx Cash from Operations (TTM) : -32.60M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -32.60M |
| March 31, 2026 | -44.42M |
| September 30, 2025 | -46.98M |
| June 30, 2025 | -48.58M |
| March 31, 2025 | -55.03M |
| September 30, 2024 | -51.64M |
| June 30, 2024 | -46.13M |
| March 31, 2024 | -45.52M |
| December 31, 2023 | -40.66M |
| September 30, 2023 | -35.01M |
| June 30, 2023 | -31.03M |
| March 31, 2023 | -31.28M |
| December 31, 2022 | -34.42M |
| September 30, 2022 | -41.11M |
| June 30, 2022 | -50.63M |
| March 31, 2022 | -47.53M |
| Date | Value |
|---|---|
| December 31, 2021 | -45.65M |
| September 30, 2021 | -45.48M |
| June 30, 2021 | -45.49M |
| March 31, 2021 | -44.50M |
| December 31, 2020 | -43.55M |
| September 30, 2020 | -49.14M |
| June 30, 2020 | -46.86M |
| March 31, 2020 | -49.77M |
| December 31, 2019 | -47.83M |
| September 30, 2019 | -39.35M |
| June 30, 2019 | -34.83M |
| March 31, 2019 | -29.64M |
| December 31, 2018 | -27.06M |
| September 30, 2018 | -22.13M |
| June 30, 2018 | -21.82M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| MediGene AG | -- |
| BioNTech SE | 725.62M |
| Immatics NV | -241.73M |
| Arrowhead Pharmaceuticals, Inc. | -59.06M |
| Oncolytics Biotech, Inc. | -26.52M |